Keep the copper in the conversation
GHK joins three amino acids, small units also found in proteins. The copper-bound version goes by GHK-Cu. The names are related, but dropping the copper changes the substance being described.
A headline can lose that distinction in a hurry. So I check whether a study used GHK, GHK-Cu or a mixture containing something else. Otherwise we may be giving one ingredient credit for another preparation’s result.
A review of topical GHK also describes problems with stability and getting it through skin. What goes into a cream matters, along with whether it reaches the place being studied. An ingredient name doesn’t answer either question.
A shorter name isn’t always a clearer description.
Two studies that need their small print
A study of men losing hair in the usual pattern used a scalp lotion combining copper-free GHK with another ingredient. The mixture increased hair counts more than the dummy lotion did. GHK-Cu wasn’t what the researchers tested.
Nor could it tell us which ingredient did how much of the work. A result for the mixture belongs to the mixture. Turning that into an injection claim would change the substance and the method of treatment at once.
Another experiment tested separate layers of human skin in a lab. Some copper passed through; some remained in the skin. Measuring that copper didn’t show that the complete peptide had arrived intact.
That’s useful work on delivery. It didn’t measure wrinkle improvement or hair growth in living people. The question it answered was narrower, and that’s fine.
Getting through skin and improving skin are different findings.
Creams and injections have different rules
Small studies of creams can’t settle injection safety. FDA flags injected GHK-Cu because peptide clumps and impurities may provoke immune reactions. The agency says there’s little human evidence to judge safety.
FDA dates the content on its safety page April 22, 2026. The injection entry sits under withdrawn nominations for compounding. That is neither clearance nor approval. The safety concerns remain beside it.
For non-injected forms, FDA’s May 14, 2026 list places GHK-Cu in Category 1. FDA describes a policy of generally not taking enforcement action when its conditions are met. That is a statement of intent, rather than approval or blanket permission to compound.
Skin products sold only for appearance follow cosmetics rules. Claims to treat disease or change the body can make a product a drug instead. There’s no FDA-approved GHK-Cu medicine.
The preparation and the way it’s used belong beside every claim.